CE Mark for DeepPath™ – LYDIA

By |2022-06-06T15:06:14+03:00June 6th, 2022|Categories: Uncategorized|Tags: , |

We are super excited to announce that DeepMedIO receives CE marking for DeepPath™ - LYDIA. The system got regulatory clearance as decision support as per IVDD for helping histopathologists detect metastases on Hematoxylin & Eosin stained lymph nodes from patients with breast cancer, colon cancer, lung cancer, and melanoma. We must note that to the best [...]